Unaudited Financial Results for the quarter ended 31st December, 2025 along with Limited review report issued by the statutory auditors of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries has announced its unaudited financial results for the quarter and nine months ended 31 December 2025, approved at a board meeting on 7 February 2026. The statutory auditors issued a standard, clean limited review report with no qualifications, adverse remarks, or emphasis-of-matter issues. The Managing Director also updated that the company's manufacturing facility upgradation project — aimed at compliance with the Revised Schedule M norms — has made significant progress, with a new warehouse block nearly complete. As of 31 December 2025, the company has spent around Rs. 65 lakhs on civil work and approximately Rs. 100 lakhs on capital expenditure, and orders have been placed for required utilities and equipment. Note: specific revenue and profit figures in the document were not legibly extractable, so quantitative comparison is not possible from this filing.
The clean auditor review and visible capex on Schedule M compliance suggest operational stability and regulatory preparedness, which is positive for the stock. However, with no clear numbers in the readable portion, investors should look at the full results table on BSE for revenue and margin trends before drawing price conclusions.